Category Archives: News

25
nov
2014
news-ccc-90x70

We are pleased to share a special nutrition program to help the pancreatic cancer community during the holidays. Learn more.

news2

A MULTI-STEP APPROACH TO DIAGNOSING PANCREATIC CANCER EARLIER

One of the reasons that pancreatic cancer is such a challenging disease is that it is frequently diagnosed once it’s reached more advanced, aggressive stages. The best opportunity for a positive outcome is when pancreatic cancer is diagnosed early, when the patient might be eligible for surgery.

Kimmel-PanCan_095_2

For every $1 invested by Pancreatic Cancer Action Network between 2003-2011, our research grant recipients have gone on to receive $9.93 in subsequent funding to support their pancreatic cancer studies.

Every grant recipient during that time has authored an average of 13 pancreatic cancer-related papers published in biomedical journals, and every paper has been read, built upon, and cited by other scientists an average of nearly eight times in other articles.

Capitol building Washington

DECEMBER 21, 2012

FOR IMMEDIATE RELEASE

THE RECALCITRANT CANCER RESEARCH ACT, FORMERLY KNOWN AS THE PANCREATIC CANCER RESEARCH & EDUCATION ACT, Passes Congress

The Pancreatic Cancer Action Network Urges President Obama to Sign the Legislation into Law

Manhattan Beach, CA (December 21, 2012) — The Recalcitrant Cancer Research Act, formerly known as the Pancreatic Cancer Research & Education Act, has passed Congress today as part of the National Defense Authorization Act and will now be sent to President Obama to sign into law. The legislation requires the National Cancer Institute (NCI) to evaluate its current efforts in studying pancreatic cancer, lung cancer, and other recalcitrant cancers, and focus on ways to improve outcomes.

Read More »

newsimg2

November 9, 2012

FOR IMMEDIATE RELEASE

STUDY SHOWS ABRAXANE® EXTENDS SURVIVAL FOR PATIENTS WITH ADVANCED PANCREATIC CANCER

MANHATTAN BEACH, CA (November 9, 2012) — The Pancreatic Cancer Action Network is pleased to announce Abraxane® extends survival for patients with advanced pancreatic cancer. According to Celgene Corporation, Abraxane in combination with gemcitabine when given to advanced pancreatic cancer patients who had not received previous treatment demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. Read More »